ProfileGDS5678 / 1443119_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 23% 23% 23% 23% 25% 25% 23% 23% 24% 23% 23% 23% 23% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.578124
GSM967853U87-EV human glioblastoma xenograft - Control 22.5413123
GSM967854U87-EV human glioblastoma xenograft - Control 32.5371523
GSM967855U87-EV human glioblastoma xenograft - Control 42.487423
GSM967856U87-EV human glioblastoma xenograft - Control 52.4849123
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6551925
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.607625
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5203323
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5170723
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5366924
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5333523
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5129223
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5407823
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5374123